John Wen-Cheng Chang

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R. Spigel, Byoung Chul Cho et al. · New England Journal of Medicine · 2024 · 208 citations

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial

Tony Mok, Te‐chun Hsia, Chun-Ming Tsai et al. · Asia-Pacific Journal of Clinical Oncology · 2011 · 47 citations · Full text

Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer

John Wen-Cheng Chang, Chun-Liang Chou, Shiu‐Feng Huang et al. · Lung Cancer · 2007 · 40 citations

Erlotinib Response, Medicine, Oncology +3

TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib

Kung‐Chu Ho, Yu-Hua Fang, Hsiao‐Wen Chung et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 28 citations

Medicine, Metastatic Lung Adenocarcinoma, Cancer Management +9

Cost‐effectiveness of bevacizumab‐based therapy versus cisplatin plus pemetrexed for the first‐line treatment of advanced non‐squamous NSCLC in Korea and Taiwan

Myung‐Ju AHN, Chun-Ming Tsai, Te‐chun Hsia et al. · Asia-Pacific Journal of Clinical Oncology · 2011 · 24 citations · Full text